The Utility of CAR-Modified T Cells in Myeloid Malignancies

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the utility of CAR-modified T cells in myeloid malignancies.

Clinical Pearls

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the utility of CAR-modified T cells in myeloid malignancies.

  • Ideally, CAR-modified T cells should have utility in myeloid malignancies
  • Identifying a target for CAR-modified T cells to recognize remains a challenge
  • There is always the danger of targeting a protein expressed on normal tissues or stem cells